UNSPSC 51162653: Tipepidine

This classification denotes an opioid receptor agonist with the molecular formula C15H17NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2260ZP67IT, chemically known as piperidine, 3-(di-2-thienylmethylene)-1-methyl- but more generally known as tipepidine, which bears US NIH Compound Identifier 5484. European Medicines Agency schedules Tipepidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11102MIG. The term TIPEPIDINE is an International Non-Proprietary Name.

UNSPSC 51162653 Tipepidine, a Commodity code, does not reflect the actual pharmaceutical procurement activity in the recent state and local opportunities tagged under it. The two most recent solicitations—one from Seminole County, Florida seeking naloxone and drug deactivation systems, and another from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and over-the-counter products—represent naloxone distribution and broader pharmaceutical supply agreements, not tipepidine procurement. State and local governments are using this code to source emergency response medications, community health supplies, and pharmaceutical inventory through both individual county health departments and multistate cooperative purchasing vehicles, but the code designation appears misaligned with the actual goods being procured.

The geographic activity shown is limited to Florida and Minnesota via MMCAP (which serves participating state and local facilities across multiple states including Oregon), with solicitations issued by Seminole County and the Minnesota Department of Administration. Seminole County posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date and may reflect a data entry error in the source). MMCAP issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with an effective date of July 1, 2026. The code shows minimal recent activity and no clear tipepidine-specific procurement signals in the available opportunities.